Amplitude Surgical SA (EPA:AMPLI)
France
· Delayed Price · Currency is EUR | Market Cap | 292.62M |
| Revenue (ttm) | 108.47M |
| Net Income (ttm) | 1.09M |
| Shares Out | 47.97M |
| EPS (ttm) | 0.02 |
| PE Ratio | 269.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,414 |
| Average Volume | 4,624 |
| Open | 6.05 |
| Previous Close | 6.10 |
| Day's Range | 6.05 - 6.10 |
| 52-Week Range | 2.70 - 6.15 |
| Beta | 0.26 |
| RSI | 72.40 |
| Earnings Date | Oct 22, 2025 |
About Amplitude Surgical
Amplitude Surgical SA designs, develops, and markets products for orthopedic surgery in France and internationally. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It also offers AMPLIVISION, a computer-assisted surgery system; the i.M.A.G.E., a single-use made-to-measure instrument system; and E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. The company ex... [Read more]
Financial Performance
In 2024, Amplitude Surgical's revenue was 106.02 million, an increase of 5.81% compared to the previous year's 100.20 million. Earnings were 1.53 million, a decrease of -96.11%.
Financial StatementsNews
Zydus Lifesciences shareholder commitments in tender offer for Amplitude Surgical
Zydus Lifesciences Limited has announced the execution of undertakings from seven shareholders to tender a total of 2,236,911 shares of Amplitude Surgical SA. These shares represent approximately 4.7%...
Zydus Life shares drop nearly 3% as UBS maintains ‘Sell’ rating
Zydus Life saw a 2.9% decline in its share price after UBS reaffirmed its ‘Sell’ rating, setting a target price of ₹850. As of 9:36 AM, the shares were trading 2.80% lower at Rs 874.65. The rating dow...
Zydus Life share price: Bank of America sees 10% potential upside on medtech expansion
Bank of America (BofA) Securities has maintained a ‘Neutral’ rating on Zydus Life, with a target price of ₹1,040, indicating potential upside from the current market price of ₹901.50 (as of March 11)....
Zydus Life share price: UBS sees downside, maintains ‘Sell’ with Rs 850 target
UBS has maintained a ‘Sell’ rating on Zydus Life, setting a target price of ₹850, indicating a downside potential from the current market price of ₹901.50 (as of March 11). The brokerage expressed con...
Stock Market news: Bharti Airtel, Zydus Life, Bharat Forge, Tata Motors, Sun Pharma among stocks to watch today on brokerage updates
Several stocks are in focus today following fresh brokerage reports. Key updates include Bharti Airtel’s tie-up with SpaceX’s Starlink, Zydus Life’s acquisition of Amplitude Surgical, and varied views...
Zydus Life in negotiations to buy French medtech firm
Zydus Lifesciences announced it is negotiating to acquire a majority stake in French medtech firm Amplitude Surgical for approximately Rs 2,500 crore. The acquisition aims to boost Zydus's global medt...
Zydus Lifesciences to acquire 85.6% stake in Amplitude Surgical SA for €256.8 million
Zydus Lifesciences Limited has announced its acquisition of an 85.6% controlling stake in Amplitude Surgical SA, a leading French MedTech company specializing in orthopedic solutions. This strategic m...